ATE378358T1 - Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen - Google Patents

Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen

Info

Publication number
ATE378358T1
ATE378358T1 AT98955631T AT98955631T ATE378358T1 AT E378358 T1 ATE378358 T1 AT E378358T1 AT 98955631 T AT98955631 T AT 98955631T AT 98955631 T AT98955631 T AT 98955631T AT E378358 T1 ATE378358 T1 AT E378358T1
Authority
AT
Austria
Prior art keywords
heparin
compounds
arterial thrombosis
glycosaminoglycans
present
Prior art date
Application number
AT98955631T
Other languages
English (en)
Inventor
Riitta Lassila
Petri Kovanen
Ken Lindstedt
Original Assignee
Jenny Ja Antti Wihurin Rahasto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenny Ja Antti Wihurin Rahasto filed Critical Jenny Ja Antti Wihurin Rahasto
Application granted granted Critical
Publication of ATE378358T1 publication Critical patent/ATE378358T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0081—Reaction with amino acids, peptides, or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066—Isolation or extraction of proteoglycans from organs
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
AT98955631T 1997-11-25 1998-11-25 Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen ATE378358T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI974321A FI974321A0 (fi) 1997-11-25 1997-11-25 Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa

Publications (1)

Publication Number Publication Date
ATE378358T1 true ATE378358T1 (de) 2007-11-15

Family

ID=8550007

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955631T ATE378358T1 (de) 1997-11-25 1998-11-25 Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen

Country Status (11)

Country Link
US (4) US20020016308A1 (de)
EP (2) EP1916260A1 (de)
JP (4) JP2001524555A (de)
AT (1) ATE378358T1 (de)
AU (1) AU764410B2 (de)
CA (1) CA2311670C (de)
DE (1) DE69838732T2 (de)
DK (1) DK1034189T3 (de)
ES (1) ES2296346T3 (de)
FI (1) FI974321A0 (de)
WO (1) WO1999026983A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
SE0000363A0 (sv) * 2000-02-04 2001-08-05 Zoucas Kirurgkonsult Ab Belagd medicinsk anordning
SE523216C2 (sv) * 2001-07-27 2004-04-06 Zoucas Kirurgkonsult Ab Heparinstent
FR2831186B1 (fr) * 2001-10-22 2004-06-18 Aventis Pharma Sa Production d'heparine a partir de cultures de mastocytes
ES2321082T3 (es) * 2002-05-09 2009-06-02 Hemoteq Ag Productos medicos que comprenden un revestimiento hemocompatible, produccion y uso de los mismos.
DE10261986B4 (de) * 2002-05-10 2008-01-31 Hemoteq Ag Hämokompatibel beschichtete Oberflächen, Verfahren zu deren Herstellung und deren Verwendungen
FR2853663B1 (fr) * 2003-04-14 2007-08-31 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
US8496953B2 (en) 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US9114194B2 (en) 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8986713B2 (en) 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
DE102008032361A1 (de) 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
RU2625756C2 (ru) 2011-03-11 2017-07-18 В.Л. Гор Энд Ассошиейтс, Инк. Усовершенствованные иммобилизованные биологические объекты
ES2926906T3 (es) * 2011-12-22 2022-10-31 Corline Biomedical Ab Medios y método para tratar vasos sanguíneos
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
US20150305892A1 (en) * 2014-04-25 2015-10-29 Abbott Cardiovascular Systems Inc. Methods and Devices for Treating a Bodily Lumen with In Situ Generated Structural Support
GB201415062D0 (en) * 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
KR102415502B1 (ko) * 2015-08-07 2022-07-01 삼성전자주식회사 복수의 사용자를 위한 라이트 필드 렌더링 방법 및 장치
CA3035659C (en) * 2016-09-16 2022-09-06 Glycologix, Llc Sulfated glycosaminoglycan biomaterials as proteoglycan mimics

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265827A (en) * 1971-03-08 1981-05-05 Monsanto Company Catalytic asymmetric hydrogenation
SE425372B (sv) * 1977-07-18 1982-09-27 Ird Biomaterial Ab Sett att heparinisera en elektriskt laddad yta pa en medecinsk artikel avsedd att komma i kontakt med blod och medel for utforande av settet
US4350629A (en) * 1981-07-29 1982-09-21 Massachusetts Institute Of Technology Procedures for preparing composite materials from collagen and glycosaminoglycan
NL188622C (nl) 1981-12-15 1992-08-17 Cordis Europ Werkwijze ter verbetering van de bloedcompatibiliteit van een materiaaloppervlak door bekleding daarvan met een heparine of heparine-analoga en een eiwit houdende film, alsmede voorwerp, omvattende een oppervlak met verbeterde bloedcompatibiliteit verkregen onder toepassing van een op het oppervlak aangebrachte heparine of heparine-analoga en een eiwit houdende film.
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
DE3639561A1 (de) * 1986-11-20 1988-06-01 Baumann Hanno Verfahren zur herstellung von nicht-thrombogenen substraten
DK505488D0 (da) 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5019393A (en) * 1988-08-03 1991-05-28 New England Deaconess Hospital Corporation Biocompatible substance with thromboresistance
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
JPH05507298A (ja) 1990-04-10 1993-10-21 ケムバイオメッド，リミテッド 非トロンボゲン性グリコサミノグリカン共重合体
FR2661332B1 (fr) 1990-04-25 1995-06-16 Michel Jean Pierre Prothese ligamentaire et son procede de fabrication.
IT1251183B (it) * 1991-08-28 1995-05-04 Opocrin Spa Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.
SE470006B (sv) * 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
WO1993006836A1 (en) * 1991-10-04 1993-04-15 Virginia Commonwealth University Von willebrand factor-specific heparin fractions
US5571166A (en) * 1992-03-19 1996-11-05 Medtronic, Inc. Method of making an intraluminal stent
CA2164226C (en) * 1993-06-04 2011-02-08 Carl H. June Methods for selectively stimulating proliferation of t cells
US5618298A (en) * 1993-10-23 1997-04-08 Simon; Michael Vascular prosthesis made of resorbable material
US7229755B1 (en) * 1993-11-17 2007-06-12 Dana Farber Cancer Institute, Inc. Method for detection of alterations in the DNA mismatch repair pathway
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
AU700584C (en) * 1994-08-12 2002-03-28 Meadox Medicals, Inc. Vascular graft impregnated with a heparin-containing collagen sealant
US5643580A (en) * 1994-10-17 1997-07-01 Surface Genesis, Inc. Biocompatible coating, medical device using the same and methods
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5702754A (en) * 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
JPH09169801A (ja) * 1995-10-17 1997-06-30 Terumo Corp ヘパリン複合体およびそれを被覆した医療器具
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5865827A (en) * 1997-06-03 1999-02-02 Bullister; Edward T Vacuum device for securing human tissue
FI974321A0 (fi) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa

Also Published As

Publication number Publication date
US20080014239A1 (en) 2008-01-17
US7314860B2 (en) 2008-01-01
AU764410B2 (en) 2003-08-21
DK1034189T3 (da) 2008-02-25
US7504113B2 (en) 2009-03-17
US20020016308A1 (en) 2002-02-07
FI974321A0 (fi) 1997-11-25
AU1240199A (en) 1999-06-15
EP1034189B1 (de) 2007-11-14
DE69838732T2 (de) 2008-10-30
EP1034189A1 (de) 2000-09-13
US20030212042A1 (en) 2003-11-13
DE69838732D1 (de) 2007-12-27
JP2011121956A (ja) 2011-06-23
CA2311670C (en) 2010-02-09
JP2011017003A (ja) 2011-01-27
CA2311670A1 (en) 1999-06-03
JP2001524555A (ja) 2001-12-04
WO1999026983A1 (en) 1999-06-03
US20090202607A1 (en) 2009-08-13
ES2296346T3 (es) 2008-04-16
US8415324B2 (en) 2013-04-09
EP1916260A1 (de) 2008-04-30
JP2011121955A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
ATE378358T1 (de) Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen
Aya et al. Hyaluronan in wound healing: rediscovering a major player
Yi et al. Toxic effects of dimethyl sulfoxide on red blood cells, platelets, and vascular endothelial cells in vitro
Luo et al. A physiologically active polysaccharide hydrogel promotes wound healing
ES2224541T3 (es) Polisacaridos sulfatados nuevos del tipo heparinicos.
Agam et al. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia
WO2004076637A3 (en) Cell-polymer fiber compositions and use thereof
DE3878918D1 (de) In-vivo-verabreichung von neurotransmittern durch implantierte eingekapselte zellen.
ES2147720T3 (es) Factor de celulas madre.
CA2093770A1 (en) Aspartic acid derivatives, their preparation and use
CN102791307A (zh) 通过体外疗法除去毒力因子
CN102766616A (zh) 从血液或血液级分中分离的凝血酶
Motolese et al. Interaction between a regenerative matrix and wound bed in nonhealing ulcers: results with 16 cases
NO20052505L (no) Ny bruk av dextran-sulfat
WO1995028907A3 (en) Megapoietin: a novel megakaryocyte growth promoting factor
ATE421319T1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
CN103083712A (zh) 掺入有干细胞或其它生物活性物质的外科敷料
Teng et al. Nitric Oxide‐Releasing Poly (L‐glutamic acid) Hybrid Hydrogels for Accelerating Diabetic Wound Healing
Zhong et al. A Photo‐induced Cross‐Linking Enhanced A and B Combined Multi‐Functional Spray Hydrogel Instantly Protects and Promotes of Irregular Dynamic Wound Healing
CN106011056A (zh) 一种用于皮肤粉刺治疗的间充质干细胞的制备方法及其产品
ITCO960031A1 (it) Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
PT1284750E (pt) Composição farmacêutica
Reignier et al. Prevention of ischemia-reperfusion lung injury by sulfated Lewisa pentasaccharide
Scarborough et al. Aggregation of platelets by muscle actin. A multivalent interaction model of platelet aggregation by ADP
Jiang et al. A Multifunctional Nanozyme Integrating Antioxidant, Antimicrobial and Pro-Vascularity for Skin Wound Management

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties